3,450 Shares in Danaher Corporation $DHR Acquired by Financial Planning Hawaii Inc.

Financial Planning Hawaii Inc. bought a new position in Danaher Corporation (NYSE:DHR) in the third quarter, HoldingsChannel.com reports. The fund bought 3,450 shares of the conglomerate’s stock, valued at approximately $764,000.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Danaher in the 2nd quarter worth $10,492,520,000. Jupiter Topco LLC bought a new stake in shares of Danaher in the second quarter worth $1,456,317,000. Generation Investment Management LLP purchased a new stake in Danaher during the second quarter valued at $1,287,949,000. Bank of America Corp DE purchased a new stake in Danaher during the second quarter valued at $993,846,000. Finally, Legal & General Group Plc bought a new position in Danaher in the second quarter valued at about $801,056,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on DHR. Wells Fargo & Company dropped their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. The Goldman Sachs Group upped their price target on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. UBS Group began coverage on shares of Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective on the stock. TD Cowen increased their price objective on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $235.41.

Danaher Stock Performance

NYSE DHR traded up $2.10 on Tuesday, hitting $223.30. 6,007,508 shares of the company traded hands, compared to its average volume of 4,462,041. The business’s 50 day moving average price is $211.85 and its 200-day moving average price is $194.88. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $156.98 billion, a price-to-earnings ratio of 39.66, a P/E/G ratio of 2.74 and a beta of 0.76.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the company earned $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. Equities analysts expect that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.